share_log

NexImmune | 8-K: Current report

NexImmune | 8-K: Current report

NexImmune | 8-K:重大事件
美股SEC公告 ·  08/27 16:06

Moomoo AI 已提取核心訊息

NexImmune, Inc. has announced significant changes to its corporate structure following the approval of the company's liquidation and dissolution by stockholders on August 9, 2024. On August 21, 2024, the entire Board of Directors, including Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao, and Leena Gandhi, tendered their resignations effective August 27, 2024. Additionally, key executive officers, including CEO Kristi Jones, CSO Mathias Oelke, and Interim CFO Albert N. Marchio II, also resigned effective the same date. These resignations were not due to any disagreements with the company's operations, policies, or practices. Concurrently, Craig Jalbert was appointed as the President, Treasurer, Corporate Secretary, and the sole member of the Board, effective August 27, 2024. Jalbert, with...Show More
NexImmune, Inc. has announced significant changes to its corporate structure following the approval of the company's liquidation and dissolution by stockholders on August 9, 2024. On August 21, 2024, the entire Board of Directors, including Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao, and Leena Gandhi, tendered their resignations effective August 27, 2024. Additionally, key executive officers, including CEO Kristi Jones, CSO Mathias Oelke, and Interim CFO Albert N. Marchio II, also resigned effective the same date. These resignations were not due to any disagreements with the company's operations, policies, or practices. Concurrently, Craig Jalbert was appointed as the President, Treasurer, Corporate Secretary, and the sole member of the Board, effective August 27, 2024. Jalbert, with over 30 years of experience in handling distressed businesses, will oversee the company's wind-down process and will be compensated $50,000 annually for three years. The Board has also approved the filing of a certificate of dissolution with the Secretary of State of Delaware, marking the commencement of the company's dissolution process. NexImmune cautions that trading in the company's securities is highly speculative and poses substantial risks, advising extreme caution for current and potential investors.
NexImmune公司宣佈,在2024年8月9日的股東批准後,其公司結構發生了重大變化,包括公司的清算和解散。2024年8月21日,整個董事會,包括Sol J. Barer,Kristi Jones,Alan S. Roemer,Tim Bertram,Paul D’Angio,Grant Verstandig,Zhengbin(Bing)Yao和Leena Gandhi,提出了辭職,辭職日期爲2024年8月27日生效。此外,包括首席執行官Kristi Jones,首席科學官Mathias Oelke和臨時首席財務官Albert N. Marchio II在內的關鍵高管也在同一日期生效辭職。這...展開全部
NexImmune公司宣佈,在2024年8月9日的股東批准後,其公司結構發生了重大變化,包括公司的清算和解散。2024年8月21日,整個董事會,包括Sol J. Barer,Kristi Jones,Alan S. Roemer,Tim Bertram,Paul D’Angio,Grant Verstandig,Zhengbin(Bing)Yao和Leena Gandhi,提出了辭職,辭職日期爲2024年8月27日生效。此外,包括首席執行官Kristi Jones,首席科學官Mathias Oelke和臨時首席財務官Albert N. Marchio II在內的關鍵高管也在同一日期生效辭職。這些辭職不是由於對公司的運營,政策或實踐的任何分歧。與此同時,Craig Jalbert被任命爲總裁,財務主管,公司秘書和董事會的唯一成員,任期爲2024年8月27日生效。Jalbert在處理公司業務困境方面擁有30多年的經驗,將負責監督公司的清算進程,並每年獲得5萬美元的補償,爲期三年。董事會還批准了向特拉華州國務卿辦公室提交解散證書,標誌着公司清算進程的開始。NexImmune提醒稱,公司證券的交易具有極高的投機性,並帶來重大風險,建議現有和潛在的投資者極度謹慎。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息